Cambridge Investment Research Advisors, Inc. Bio Xcel Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 38,050 shares of BTAI stock, worth $19,405. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,050
Previous 38,050
-0.0%
Holding current value
$19,405
Previous $49,000
53.06%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$612,7020.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$224,7490.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$152,0010.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$94,3790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$66,2330.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $14.3M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...